GEO DataSets

Analysis of 9 individual patient-derived, pancreatic ductal adenocarcinoma (PDAC) xenografts treated with GSI MRK-003. MRK-003 monotherapy significantly reduced tumor volume in 5 of 9 xenografts. Results provide insight into the molecular basis of MRK-003-mediated attenuation of PDAC.

Organism:

Homo sapiens

Type:

Expression profiling by array, count, 9 cell line, 2 other sets

Platform:

GPL570

Series:

GSE37645

18 Samples

Download data: CEL

(Submitter supplied) Pancreatic ductal adenocarcinoma (PDAC) is a nearly uniformly lethal malignancy, with most patients facing an adverse clinical outcome. Given the pivotal role of aberrant Notch signaling in the initiation and progression of PDAC, we investigated the effect of MRK-003, a potent and selective γ-secretase inhibitor, in preclinical PDAC models. We used a panel of human PDAC cell lines, as well as patient-derived PDAC xenografts, to determine whether pharmacological targeting of the Notch pathway could inhibit pancreatic tumor growth and potentiate gemcitabine sensitivity. more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Dataset:

GDS4342

Platform:

GPL570

18 Samples

Download data: CEL

(Submitter supplied) Next generation sequencing was used to identify Notch mutations in a large collection of diverse solid tumors. NOTCH1 and NOTCH2 rearrangements leading to constitutive receptor activation were confined to triple negative breast cancers (TNBC, 6 of 66 tumors). TNBC cell lines with NOTCH1 rearrangements associated with high levels of activated NOTCH1 (N1-ICD) were sensitive to the gamma-secretase inhibitor (GSI) MRK-003, both alone and in combination with pacitaxel, in vitro and in vivo, whereas cell lines with NOTCH2 rearrangements were resistant to GSI. more...

Organism:

Homo sapiens

Type:

Expression profiling by high throughput sequencing

Platform:

GPL11154

27 Samples

Download data: TXT

(Submitter supplied) mRNA profiling data for 58 breast cancer cell lines at baseline

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL10379

58 Samples

Download data: CEL

(Submitter supplied) The CREB binding protein inhibitor ICG-001 suppresses pancreatic cancer growth We used microarrays to detail global gene expression changes in the pancreatic cancer cell line AsPC1 following treatment with ICG-001 or siRNA-mediated knockdown of CTNNB1 (beta-catenin)

Organism:

Homo sapiens

Type:

Expression profiling by array

Datasets:

GDS5323 GDS5324

Platform:

GPL570

16 Samples

Download data: CEL

Analysis of AsPc1 pancreatic adenocarcinoma cells depleted for beta-catenin. Dysregulation of Wnt/β-catenin signaling is implicated in the pathogenesis of cancers. Results compared to those from AsPC1 cells treated with the CREB-binding protein inhibitor ICG-001 (GDS5323).

Organism:

Homo sapiens

Type:

Expression profiling by array, count, 2 protocol sets

Platform:

GPL570

Series:

GSE57728

4 Samples

Download data: CEL

Analysis of AsPC1 pancreatic adenocarcinoma (PDAC) cells treated with IGC-001 up to 24 hours. IGC-001 binds to CREB-binding protein to disrupt its interaction with β-catenin. Results compared to β-catenin depletion (GDS5324) and provide insight into the therapeutic potential of IGC-001 in PDAC.

Organism:

Homo sapiens

Type:

Expression profiling by array, count, 2 agent, 2 time sets

Platform:

GPL570

Series:

GSE57728

12 Samples

Download data: CEL

(Submitter supplied) Despite advances in molecular pathogenesis, pancreatic cancer remains a major unsolved health problem. It is a rapidly invasive, metastatic tumor that is resistant to standard therapies. The phosphatidylinositol-3-kinase (PI3K)/Akt and mammalian target of rapamycin (mTOR) signaling pathways are frequently dysregulated in pancreatic cancer. Gemcitabine (Gem) is the mainstay treatment for metastatic pancreatic cancer. more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL15371

14 Samples

Download data: TXT

(Submitter supplied) Intrahepatic Cholangiocarcinoma (iCCA) is a deadly disease with rising incidence and few treatment options. Recently, aberrant Notch signaling was reported in iCCA carcinogenesis. Specifically, altered expression and/or activation of the receptors Notch1/2 suggests a role for Notch pathway overactivation during iCCA formation and progression. In this study, we examined the effects of Notch inhibition by γ-secretase inhibitor, LY3039478 in human iCCA cell lines and in an excellent patient derived-xenograft (PDX) model. more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL17586

11 Samples

Download data: CEL, CHP

(Submitter supplied) Pancreatic tumors with small size can cause type3C Diabetes Mellitus (PCA-DM) but the mechanism is unknown. In this study we aimed at revealing the mRNA and long noncoding RNA (LncRNA) expression patterns of pancreatic tumors that triggered PCA-DM. Four pancreatic tumors from patients with PCA-DM (A1-A4), four pancreatic tumors from patients without PCA-DM (B1-B4), and four pancreatic tissues from patients with pancreatitis were individually profiled with Agilent microarrays(Arraystar Human LncRNA Array v3.0).

Organism:

Homo sapiens

Type:

Expression profiling by array; Non-coding RNA profiling by array

Platform:

GPL16956

12 Samples

Download data: TXT

(Submitter supplied) Gemcitabine constitutes one of the backbones for chemotherapy treatment in pancreatic ductal adenocarcinoma (PDAC) but patients often show poor or complete lack of response to this agent. Molecular markers downstream of Gemcitabine treatment in pre-clinical models may provide an insight into resistance mechanisms. We identified potential secretory biomarkers of Gemcitabine resistance (response) in the transgenic KRasG12D; Trp53R172H; Pdx-1 Cre (KPC) mouse model of PDAC using cytokine arrays. more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL10558

12 Samples

Download data: IDAT, TXT

(Submitter supplied) Human pancreatic ductal adenocarcinoma (PDAC) involves the dysregulation of multiple signalling pathways. A novel approach to the treatment of PDAC is described, involving the targeting of cancer genes in PDAC pathways having over-representation of G-quadruplexes, using the quadruplex-binding compound CM03. This has been designed by computer modelling, is a potent inhibitor of cell growth in PDAC cell lines and has anti-cancer activity in PDAC models, with a superior profile compared to gemcitabine, a commonly used therapy. more...

Organism:

Homo sapiens

Type:

Expression profiling by high throughput sequencing

Platform:

GPL18573

104 Samples

Download data: TXT

(Submitter supplied) Pancreatic ductal adenocarcinoma (PDAC) often presents at late clinical stages, and most patients are managed solely through palliative chemotherapy. With no approved treatment modalities for patients who progress on broad-spectrum chemotherapy, we set to identify druggable targets to prevent or reverse resistance to the first line anti-neoplastic Gemcitabine. In our first experiment, we used the well-established Panc1 cell line as an in vitro model of PDAC. more...

Organism:

Homo sapiens

Type:

Expression profiling by high throughput sequencing

Platforms:

GPL18573 GPL24676

6 Samples

Download data: RDS, TAR, TXT

(Submitter supplied) Pancreatic cancer (pancreatic ductal adenocarcinoma: PDAC) is one of the most aggressive neoplastic diseases. Metformin use was associated with reduced pancreatic cancer incidence or better survival in diabetics. Metformin has been shown to inhibit PDAC cells survival and growth in vitro and in vivo. However, clinical trials using metformin failed to decrease pancreatic cancer progression in patients, raising important questions about molecular mechanisms that protect tumor cells from the antineoplastic activities of metformin. more...

Organism:

Homo sapiens

Type:

Expression profiling by high throughput sequencing

Platform:

GPL24676

12 Samples

Download data: TXT

(Submitter supplied) This SuperSeries is composed of the SubSeries listed below.

Organism:

Homo sapiens; Mus musculus

Type:

Expression profiling by high throughput sequencing

Platforms:

GPL18573 GPL19057

23 Samples

Download data

(Submitter supplied) To interrogate transcriptomic changes in highly liver metastatic pancreatic ductal carcinoma cells as relative to their isogenic lowly metastatic cells

Organism:

Homo sapiens

Type:

Expression profiling by high throughput sequencing

Platform:

GPL18573

11 Samples

Download data: CSV

(Submitter supplied) To interrogate transcriptomic changes in highly liver metastatic pancreatic ductal carcinoma cells as relative to their isogenic lowly metastatic cells

Organism:

Homo sapiens; Mus musculus

Type:

Expression profiling by high throughput sequencing

Platforms:

GPL19057 GPL18573

12 Samples

Download data: CSV